• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Investor Action Reminder: The Schall Law Firm Encourages Investors in Organogenesis Holdings Inc. with Losses of $100,000 to Contact the Firm

By: NewMediaWire
January 25, 2022 at 14:31 PM EST

Los Angeles - (NewMediaWire) - January 25, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Organogenesis Holdings Inc. (“Organogenesis” or “the Company”) (NASDAQ: ORGO) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 17, 2021 and October 11, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before February 8, 2022.  

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Organogenesis improperly billed the government for Affinity and PuraPly XT using multiple tactics such as setting prices much higher than competing products. The Company influenced physicians to use its products through reimbursement programs. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Organogenesis, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

 

SOURCE:

The Schall Law Firm

View the original release on www.newmediawire.com

More News

View More
D-Wave: Reevaluating the Short Seller’s Case After the Downgrade
Today 17:38 EDT
Via MarketBeat
Tickers QBTS RGTI
Datavault: A Speculative AI Play, But Beware of Volatility
Today 16:42 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers DVLT IBM SCLX
Traders Are Piling Into Suncor Call Options—Should You?
Today 14:28 EDT
Via MarketBeat
Topics World Trade
Tickers SU
Delta Air Lines Stock Looks Ready to Fly to New Highs
Today 13:44 EDT
Via MarketBeat
Tickers DAL
2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk
Today 12:12 EDT
Via MarketBeat
Topics Artificial Intelligence
Tickers ABSI MRK RXRX
Recent Quotes
View More
Symbol Price Change (%)
GOOG  244.64
+7.15 (3.01%)
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap